These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6056370)

  • 41. [Problems of drug safety].
    Liljestrand A
    Nord Med; 1967 Nov; 78(47):1535-9. PubMed ID: 6075272
    [No Abstract]   [Full Text] [Related]  

  • 42. Global perspective on specifications for biotechnology products--perspective from Japan.
    Hayakawa T
    Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678
    [No Abstract]   [Full Text] [Related]  

  • 43. International Conference on Harmonisation; guidance on Q9 Quality Risk Management; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jun; 71(106):32105-6. PubMed ID: 16795933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Manufacturers' warranty for drug products.
    Roffe BD; Solomon DK
    Am J Hosp Pharm; 1982 Sep; 39(9):1456-7. PubMed ID: 7137179
    [No Abstract]   [Full Text] [Related]  

  • 45. A pathologist's view-point on quality assurance of pharmaceutical products.
    Lumb G
    Med Serv J Can; 1967 Mar; 23(3):370-5. PubMed ID: 6056379
    [No Abstract]   [Full Text] [Related]  

  • 46. [Dossier of prescription preparations].
    Vanhalle G; Hanquin PJ
    J Pharm Belg; 1996; 51(5):237-84. PubMed ID: 9011601
    [No Abstract]   [Full Text] [Related]  

  • 47. LyphoMed sparks worries.
    Wagner M
    Mod Healthc; 1988 Jul; 18(29):5. PubMed ID: 10325202
    [No Abstract]   [Full Text] [Related]  

  • 48. Negotiating reality: the construction of enforceable pharmaceutical standards.
    Parrish RH
    Food Drug Law J; 2002; 57(3):457-74. PubMed ID: 12710406
    [No Abstract]   [Full Text] [Related]  

  • 49. Extra-label drug use--pharmaceutical industry view.
    Welser JR
    J Am Vet Med Assoc; 1993 May; 202(10):1635-42;discussion 1654-8. PubMed ID: 8514571
    [No Abstract]   [Full Text] [Related]  

  • 50. What's best for the patient?
    Burkle WS
    Am J Hosp Pharm; 1983 Apr; 40(4):558. PubMed ID: 6846359
    [No Abstract]   [Full Text] [Related]  

  • 51. [Doctors as naive (innocent) drug advertisers].
    Shoenfeld Y
    Harefuah; 2008 Feb; 147(2):98-9. PubMed ID: 18357661
    [No Abstract]   [Full Text] [Related]  

  • 52. [Some aspects on drug safety control].
    Pekkarienen A
    Nord Med; 1967 Nov; 78(47):1539-42. PubMed ID: 6075273
    [No Abstract]   [Full Text] [Related]  

  • 53. Reporting drug defects.
    Belson JJ
    Hosp Formul; 1975 Feb; 10(2):78-9. PubMed ID: 10316674
    [No Abstract]   [Full Text] [Related]  

  • 54. Rx: Canadian drugs.
    Rawson NS
    N Engl J Med; 2004 Mar; 350(11):1155. PubMed ID: 15017685
    [No Abstract]   [Full Text] [Related]  

  • 55. [Harmful effects of drugs. Liability of the manufacturers against insurance claims for damages].
    Dahl B
    Ugeskr Laeger; 1984 Sep; 146(36):2726-8. PubMed ID: 6515894
    [No Abstract]   [Full Text] [Related]  

  • 56. [Novae and other iniquities in pharmacotherapy].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1984 Jan; 128(1):26-30. PubMed ID: 6694762
    [No Abstract]   [Full Text] [Related]  

  • 57. Voluntary standards--the USP and the PDA.
    Schmitz AJ
    J Parenter Drug Assoc; 1980; 34(6):425-6. PubMed ID: 6906364
    [No Abstract]   [Full Text] [Related]  

  • 58. [How, when and why do the drugs go out of date].
    Lapinjoki S
    Duodecim; 2001; 117(2):187-91. PubMed ID: 12092372
    [No Abstract]   [Full Text] [Related]  

  • 59. Spurious drugs.
    Mittal SB
    J Indian Med Assoc; 2000 Aug; 98(8):464. PubMed ID: 11294333
    [No Abstract]   [Full Text] [Related]  

  • 60. Development of specifications for biotechnology products--perspective from Europe.
    Trouvin JH
    Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.